Molecular Warehouse, backed by Oxford Technology, has a disruptive, patent-pending biosensor technology designed to enable people to monitor their health using their smartphones. First applications will be for kidney transplantation and chronic stress. The in vitro diagnostic device market is $58bn.
- Obtained £1.2m in funding since incorporation in March 2015
- Comprehensive IP strategy with 5 international patents filed
- Hardware prototype and MVP for App and Web dashboard developed
- Experienced team and backing from specialised VCs
Each year, millions of people die because they didn’t know they had a health problem, or because they learnt about it too late.
Our vision is to create a world where most diseases are prevented, by giving people the ability to monitor and manage their health using their smartphones, anywhere, anytime.
To achieve this, we are working to re-engineer the most successful personal diagnostic system, the glucose monitor, which millions of diabetic patients use every day, to be able to detect many other diseases.
For our first tests we focus on helping kidney disease patients. Almost 10% of the population worldwide suffer chronic kidney disease, and there are 2m patients in dialysis and 1m patients with a kidney transplant.
Poor monitoring and drug adherence cause 36% of kidney graft losses, and 20% of dialysis patients die while they wait for a new kidney. With our system, patients will be able to monitor themselves at home, and communicate the results with their doctor.
We are expanding to multiple other applications, such as chronic stress and heart disease, so we can help not just millions, but hundreds of millions of people worldwide.
– Raised over £635K in equity funding since incorporation in March 2015
– Secured £570K in grants for development of our first tests
– Comprehensive IP strategy with 5 international patents filed
– Developed hardware prototype and MVP for App and Web dashboard